Methylene Blue and Microcirculation in Septic Shock
Primary Purpose
Septic Shock
Status
Unknown status
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Methylene Blue
Norepinephrine infusion
Sponsored by
About this trial
This is an interventional treatment trial for Septic Shock
Eligibility Criteria
Inclusion Criteria:
- Septic shock
- The patient is on norepinephrine infusion
Exclusion Criteria:
- Elevated serum creatinine (above 1.4 mg/dL)
- Pregnancy
Sites / Locations
- Cairo University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
methylene blue group
Norepinephrine group
Arm Description
The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
The patients in this group will receive norepinephrine infusion.
Outcomes
Primary Outcome Measures
Microvascular flow index
The image will be divided into four quadrants and the vessels <20 μ m diameter will be assigned a score based on the predominant flow characteristics of the vessels in that quadrant (0 = absent flow; 1 = intermittent; 2 = sluggish; 3 = normal). The values in each quadrant will be averaged to give an microvascular flow index for each sublingual site at each time point. To determine heterogeneity of perfusion, the flow heterogeneity index will be calculated as the highest microvascular flow index minus the lowest microvascular flow index divided by the mean microvascular flow index.
Secondary Outcome Measures
Total vessel density
The number of vessels per millimeters squared.
Perfused vessel density
The number of vessels multiplied by the fraction of perfused vessels
Proportion of perfused vessel
The number of vessels with flows 2 and 3 divided by the total number of vessels and multiplied by 100.
mean arterial pressure
the mean arterial blood pressure measured in mmHg
serum lactate
the value of lactate in the serum measured in milligrams per liter
length of stay in the intensive care unit
the duration of stay in the intensive care unit measured in days
cardiac output
The amount of blood ejected by the heart in one minute measured in liters
total consumption of norepinephrine
the total consumption of norepinephrine in 6 hours measured in micrograms.
incidence of mortality
The number of dead patients divided by the total number of patients
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04295993
Brief Title
Methylene Blue and Microcirculation in Septic Shock
Official Title
The Effect of Methylene Blue on Microcirculation in Patients With Septic Shock: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 10, 2020 (Anticipated)
Primary Completion Date
September 10, 2020 (Anticipated)
Study Completion Date
September 20, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This trial aims to identify the effects of methylene blue infusion on the the micro-circulation in patients with septic shock. The investigators will evaluate various indices of micro-circulation such as: microvascular flow index, the flow heterogeneity index, the total vessel density, the perfused vessel density, and the proportion of perfused vessels.
Detailed Description
The mortality rate of patients with septic shock remains very high. Arterial hypotension, related to arteriolar vasodilation and myocardial depression are the mainstays of septic shock pathology.
At the level of the micro-circulation, there is insufficient delivery of oxygen to organs and tissues which results in organ dysfunction and potential organ necrosis.One key factor leading to vascular dysfunction is the inappropriately increased production of nitric oxide within the blood vessel endothelium. Elevated levels of nitric oxide results in the blood vessel endothelium receiving direct vasodilator input, as well as the inability to respond to norepinephrine-mediated vasoconstriction. Nitric oxide activates the soluble isoform of the enzyme guanylatecyclase, which in turn increases production of cyclic guanosine monophosphate. Nitric oxide has other beneficial effects which are mediated via other pathways than guanylatecyclase; therefore, administration of a guanylate cyclase inhibitor such as methylene blue could be a safer therapeutic option than the inhibition of nitric oxide production.
These effects of methylene blue could be related to vasoconstriction and positive inotropic effects as well to an increase in blood volume, itself related to a decrease in vascular permeability. The use of methylene blue has been recently advocated as a potential adjunct in the treatment of shock states. However, the effect of MB at the level of the capillary bed, where vital exchange of oxygen and nutrients occurs, is unknown. Thus in this study, the investigators will investigate the effect of methylene blue in combination with NE at the microvascular level in septic shock.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
32 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
methylene blue group
Arm Type
Experimental
Arm Description
The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
Arm Title
Norepinephrine group
Arm Type
Active Comparator
Arm Description
The patients in this group will receive norepinephrine infusion.
Intervention Type
Drug
Intervention Name(s)
Methylene Blue
Intervention Description
The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
Intervention Type
Drug
Intervention Name(s)
Norepinephrine infusion
Other Intervention Name(s)
Levophed
Intervention Description
The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
Primary Outcome Measure Information:
Title
Microvascular flow index
Description
The image will be divided into four quadrants and the vessels <20 μ m diameter will be assigned a score based on the predominant flow characteristics of the vessels in that quadrant (0 = absent flow; 1 = intermittent; 2 = sluggish; 3 = normal). The values in each quadrant will be averaged to give an microvascular flow index for each sublingual site at each time point. To determine heterogeneity of perfusion, the flow heterogeneity index will be calculated as the highest microvascular flow index minus the lowest microvascular flow index divided by the mean microvascular flow index.
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Total vessel density
Description
The number of vessels per millimeters squared.
Time Frame
6 hours
Title
Perfused vessel density
Description
The number of vessels multiplied by the fraction of perfused vessels
Time Frame
6 hours
Title
Proportion of perfused vessel
Description
The number of vessels with flows 2 and 3 divided by the total number of vessels and multiplied by 100.
Time Frame
6 hours
Title
mean arterial pressure
Description
the mean arterial blood pressure measured in mmHg
Time Frame
24 hours
Title
serum lactate
Description
the value of lactate in the serum measured in milligrams per liter
Time Frame
6 hours
Title
length of stay in the intensive care unit
Description
the duration of stay in the intensive care unit measured in days
Time Frame
28 days
Title
cardiac output
Description
The amount of blood ejected by the heart in one minute measured in liters
Time Frame
24 hours
Title
total consumption of norepinephrine
Description
the total consumption of norepinephrine in 6 hours measured in micrograms.
Time Frame
6 hours
Title
incidence of mortality
Description
The number of dead patients divided by the total number of patients
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Septic shock
The patient is on norepinephrine infusion
Exclusion Criteria:
Elevated serum creatinine (above 1.4 mg/dL)
Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
kareman abdelghaffar, Demonstrator
Phone
+201223931469
Email
kareman_86@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed Hasanin, Professor
Phone
+201095076954
Email
ahmedmohamedhasanin@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed Mukhtar, Professor
Organizational Affiliation
Professor of anesthesia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cairo University
City
Cairo
Country
Egypt
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashraf Rady, Professor
Email
ashrafrady83@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Methylene Blue and Microcirculation in Septic Shock
We'll reach out to this number within 24 hrs